The abstract is read at the publisher; the summary is JClub's.
In a Northern California cohort of adults with ASCVD and LDL-C ≥70 mg/dL, lipid-lowering therapy was not escalated in 11,842 of 13,354 relevant notes (88.7%).
- Why it matters: Guidelines recommend treat-to-target LDL-C management in secondary prevention, yet LLT escalation remains underused. Knowing when and why clinicians do not intensify therapy could help close guideline-discordant care gaps.
- What they did: A retrospective study (Jan 1, 2019–May 15, 2025) used state-of-the-art large language models to extract LDL-C targets, LLT adjustments, and nonescalation reasons from most recent clinical notes, evaluated against clinical annotations.
- The result: A treat-to-target strategy was identified in 3,756 (28.1%) of relevant notes, and nonescalation reasons appeared in 4,788 (40.4%), most often patient-reported adverse effects (1,683; 12.6%), near-goal LDL-C (922; 6.9%), and patient preference to avoid LLT (914; 6.8%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.